Comoglu Tansel, Inal Ozge, Yaacoub Hajar Ben
a Faculty of Pharmacy, Department of Pharmaceutical Technology , Ankara University , Tandogan , Ankara , Turkey.
Pharm Dev Technol. 2016 Dec;21(8):901-908. doi: 10.3109/10837450.2015.1022792. Epub 2015 Mar 23.
Drugs exhibiting satisfactory absorption from the oral mucosa or intended for immediate pharmacological action can be advantageously formulated as orally fast-disintegrating tablets (FDTs or ODTs). Therefore, taste masking of active ingredients becomes essential in these systems because the drug is entirely released in the mouth. Despite advances in the FDT technologies, formulation of drugs with a bitter taste is still a challenge, especially when the amount of drug is high. In this study, a new solution is being developed to incorporate higher doses of a model bitter taste drug; ketoprofen, without affecting the fast-disintegrating properties of the formulation. The unpleasant taste of the active drug usually masked by adding flavoring ingredients and sweeteners to improve taste and palatability but in this study a novel approach of using a polymer; Eudragit EPO and a granulation procedure of this polymer with the active drug was applied to mask the bitter taste of ketoprofen. In order to produce ketoprofen FDT formulations, a two-stepped procedure was followed; granulation process with the taste-masking agent (Eudragit EPO) and then direct compression (F3 and F4). In F1 and F2 formulations, granulation process was not implemented in order to observe the effect of application method of Eudragit EPO. As well as observing the effect of taste-masking agent, crospovidone and sodium starch glycolate were used in different concentrations (2, 4 and 8wt%) to examine the influence of superdisintegrants on FDT properties. All the FDTs containing 30 mg ketoprofen (F1, F2, F3 and F4) were evaluated by means of in vitro quality control tests.
从口腔黏膜吸收良好或旨在产生即时药理作用的药物,可有利地制成口腔速崩片(FDTs或ODTs)。因此,在这些制剂中,活性成分的掩味至关重要,因为药物在口腔中完全释放。尽管FDT技术取得了进展,但对于苦味药物的制剂而言,仍是一项挑战,尤其是当药物剂量较高时。在本研究中,正在开发一种新的解决方案,以纳入更高剂量的模型苦味药物;酮洛芬,同时不影响制剂的速崩性能。活性药物的 unpleasant taste通常通过添加调味成分和甜味剂来掩盖,以改善口感和适口性,但在本研究中,采用了一种 novel approach,即使用聚合物;Eudragit EPO,并将该聚合物与活性药物进行制粒程序,以掩盖酮洛芬的苦味。为了制备酮洛芬FDT制剂,采用了两步法;用掩味剂(Eudragit EPO)进行制粒过程,然后直接压片(F3和F4)。在F1和F2制剂中,未进行制粒过程,以观察Eudragit EPO的应用方法的效果。除了观察掩味剂的效果外,还使用了不同浓度(2、4和8wt%)的交联聚维酮和淀粉乙醇酸钠,以研究超级崩解剂对FDT性能的影响。所有含30mg酮洛芬的FDTs(F1、F2、F3和F4)均通过体外质量控制试验进行评估。